Abstract
Purpose
To investigate the efficacy of using surgical glove (SG) compression therapy to prevent nanoparticle albumin-bound paclitaxel (nab-PTX)-induced peripheral neuropathy.
Patients and methods
Patients with primary and recurrent breast cancer who received 260 mg/m2 of nab-PTX were eligible for this case-control study. Patients wore two SGs of the same size, i.e., one size smaller than the size that fit their dominant hand, for only 90 min. They did not wear two SGs on the non-dominant hand, which served as the control hand. Peripheral neuropathy was evaluated at each treatment cycle using common terminology criteria for adverse events (CTCAE) version 4.0 and the Patient Neurotoxicity Questionnaire. The temperature of each fingertip of the compression SG-protected hand and control hand was measured using thermography.
Results
Between August 2013 and January 2016, 43 patients were enrolled and 42 were evaluated. The occurrence rates of CTCAE grade 2 or higher sensory and motor peripheral neuropathies were significantly lower for SG-protected hands than for control hands (sensory neuropathy 21.4 vs. 76.1 %; motor neuropathy 26.2 vs. 57.1 %). No patients withdrew from this study because they could not tolerate the compression from the SGs. SG compression therapy significantly decreased the temperature of each fingertip by 1.6–2.2 °C as compared with the temperature before chemotherapy (p < 0.0001).
Conclusions
SG compression therapy is effective for reducing nab-PTX-induced peripheral neuropathy. The nab-PTX exposure to the peripheral nerve may be decreased because the SG decreases microvascular flow to the fingertip.
Similar content being viewed by others
References
Blumenthal DT (2009) Assessment of neuropathic pain in cancer patients. Curr Pain Headache Rep 13:282–287
Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15–49
Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(suppl 1):S8–S19
Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivative. Acta Oncol 54:587–591
Yamamoto Y, Kawano I, Iwase H (2011) Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 4:123–136
Yamada K, Yamamoto N, Yamada Y et al (2010) Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 40:404–411
Rivera E, Cianfrocca M (2015) Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 75:659–670
Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803
Gradishar WJ, Krasnojon D, Cheporov S et al (2012) Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final overall survival (OS) analysis of a randomized phase 2 trial. Clin Breast Cancer 12:313–321
Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy- induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967
Scotté F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23:4424–4429
Eckhoff L, Knoop AS, Jensen MB et al (2013) Risk of docetaxel-induced peripheral neuropathy among 1725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 142:109–118
Ohno T, Mine T, Yoshioka H et al (2014) Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer. Anticancer Res 34:4213–4216
Nakamura S, Iwata H, Funato Y, Ito K, Ito Y (2015) Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer. Gan To Kagaku Ryoho 42(4):447–455
Pachman DR, Barton DL, Watson JC et al (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387
Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6:455–467
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642
Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367
Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866–871
Shigematsu H, Kadoya T, Masumoto N et al (2015) The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer 15(2):110–116
McArthur HL, Rugo H, Nulsen B et al (2011) A Feasibility study of Bevacizumab plus dose-dense doxorubicin–cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 17(10):3398–3407
Robert N, Krekow L, Stokoe C et al (2011) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Res Treat 125(1):115–120
Acknowledgements
We thank Prof. Toshiro Katayama of the Faculty of Health Sciences, Department of Medical Engineering, Himeji Dokkyo University (Himeji, Hyogo, Japan) for critically reviewing the statistical analysis of our study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Nobuyuki Katakami received research funds from AstraZeneca, Eisai, Ono Pharmaceutical, Kyowa Hakko Kirin, Shionogi Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, Lilly, Beohringer Ingelheim, Merck Serono, MSD, Maruishi Pharma, Astellas Pharma, Bristol-Myers Squibb, and Amgen. All remaining authors have no conflicts of interest to declare.
Ethical approval
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Tsuyuki, S., Senda, N., Kanng, Y. et al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat 160, 61–67 (2016). https://doi.org/10.1007/s10549-016-3977-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-3977-7